

# Hansa Medical

- PRESS RELEASE -  
June 11, 2014

Hansa Medical to present IdeS at the 2014 BIO International Convention in San Diego, USA, on June 26

**Hansa Medical will present the drug candidate IdeS, currently in clinical development, as a method for desensitization prior to kidney transplantation, at 10:15 a.m. in the convention's venue Mission Beach.**

The 2014 BIO International Convention (*Biotechnology Industry Organization*), June 23 through 26, will be held at the San Diego Convention Center in San Diego, California. The convention gathers international and US-based industry leading parties, prominent keynote speakers, and attracts extensive media coverage.

For more information about the event, please visit: [www.convention.bio.org](http://www.convention.bio.org)

The CEO presentation will emphasize IdeS' promising deactivating effect on IgG-antibodies, recently established in a clinical Phase I study and IdeS' potential as a novel treatment in enabling transplantation in sensitized patients.

## **More on IdeS**

The enzyme IdeS is developed as a fast, safe and expedient method to deactivate anti-HLA antibodies in sensitized patients prior to kidney transplantation. For sensitized patients, anti-HLA antibodies pose the primary obstacle to become transplanted, and the patients are referred to long-term dialysis. A successful Phase I-study with IdeS was finalized in January 2014. A Phase II study application for treatment of sensitized kidney transplantation patients has been approved by the Swedish Medical Products Agency, and the study is scheduled for 2014.

## **For further information, please contact:**

Hansa Medical AB  
Emanuel Björne, CEO  
Mobile: +46 707 17 54 77  
E-mail: [emanuel.bjorne@hansamedical.com](mailto:emanuel.bjorne@hansamedical.com)